Logo Image
|Videos|February 23, 2022

Contemporary OB/GYN Journal

  • Vol 67 No 3
  • Volume 67
  • Issue 3

Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents

Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.

If approved, relugolix, estradiol, and norethindrone acetate tablets (Myfembree; Myovant Sciences, Pfizer) could be game-changing for pain management in women with moderate-to-severe endometriosis pain.

Articles in this issue

over 4 years ago

Delayed diagnosis of a bowel injury at laparoscopy

over 4 years ago

In this issue: Adnexal torsion, abnormal uterine bleeding, and endometriosis awareness month

over 4 years ago

Understanding abnormal uterine bleeding in adolescents

over 4 years ago

Adnexal torsion requires careful diagnosis, management

over 4 years ago

Bringing awareness to endometriosis

over 4 years ago

Celebrating Laura E. Riley, MD

over 4 years ago

Women with pelvic pain turn to social media for condition information, management

over 4 years ago

Prenatal genetic data sharing and privacy risks

over 4 years ago

Patient perspectives on vulvovaginal candidiasis

over 4 years ago

Provider bias in contraceptive counseling

Related Content